buprenorphine extended-release · SUBLOCADE

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Opioid Use Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
CA
  • Moderate to severe opioid use disorder in adults stabilised on a transmucosal buprenorphine product
Product first approved 2018biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Opioid Use Disorder
NCT05164549 · King's College London
2019-08-06 – 2023-03-01 · Opiate Substitution Treatment
What this study did
NCT04523792 · Virginia Commonwealth University
2021-01-01 – 2021-12-31 · Opioid Use Disorder
What this study did
NCT03818399 · Virginia Commonwealth University
2019-01-04 – 2021-02-24 · Opioid Use Disorder
What this study did
NCT02896296 · Indivior Inc.
2016-08-17 – 2017-08-23 · Opioid Use Disorder, Opioid-related Disorders
What this study did
Other / comorbidity
NCT03809143 · The University of New South Wales
2019-05-22 – 2021-03-30 · Opioid Dependence
What this study did
Phase 2 (4)
Opioid Use Disorder
NCT05991622 · Rhode Island Hospital
2022-04-01 – 2026-02-13 · Human Immunodeficiency Virus, Opioid Use Disorder
What this study did
NCT06576843 · Indivior Inc.
2024-09-17 – 2026-01-21 · Moderate to Severe Opioid Use Disorder
What this study did
Other / comorbidity
NCT03744663 · Wake Forest University Health Sciences
2022-06 – 2022-12 · Opioid Use
What this study did
Phase 1/2 (1)
Opioid Use Disorder
NCT03861338 · New York State Psychiatric Institute
2019-03-01 – 2020-02-28 · Opioid-use Disorder
What this study did
Phase 1 (3)
Opioid Use Disorder
NCT03002961 · Indivior Inc.
2012-07 – 2013-10 · Opioid Use Disorder
What this study did
NCT02765867 · Indivior Inc.
2010-11 – 2011-05 · Opioid Use Disorder
What this study did
Phase 4 (6)
Opioid Use Disorder
NCT06880718 · Lifespan
2026-02-18 – 2027-06 · Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder, Buprenorphine
What this study did
NCT07439549 · Pouya Azar
2026-04-29 – 2026-09-30 · Opioid Use Disorder
What this study did
NCT05704543 · Indivior Inc.
2023-03-01 – 2023-11-01 · Opioid Use Disorder
What this study did
NCT04060654 · Indivior Inc.
2019-10-21 – 2020-05-15 · Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
What this study did
NCT03993392 · Indivior Inc.
2019-08-29 – 2019-12-26 · Opioid-use Disorder
What this study did

Competitive landscape

This drug's own stage for Opioid Use Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Buprenorphine Extended-Release (SUBLOCADE): this drugApprovedSmall moleculeMu-opioid receptor (partial agonist)Weak signalFeatured results are non-efficacy only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SUBLOCADE (buprenorphine extended-release) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 4Opioid Use DisorderRecruiting
Est. primary completion 2027-01 · NCT06880718 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 February 2025ApprovalFDA approves SUBLOCADE label changes (rapid initiation, alternative injection sites)
US, FDA · Source ↗